LINC02362 attenuates hepatocellular carcinoma progression through the miR-516b-5p/SOSC2 axis

Figure 5.LINC02362 sponges miR-516b-5p to mitigate the enhancement of HCC cell survival. (A, B) RT-qPCR quantification of miR-516b-5p (A) and LINC02362 (B) expression in Hep3B and PLC/PRF/5 cells (n=3). (C) MTT assay (n=3) for measuring the proliferative abilities of HCC cells overexpressing miR-516b-5p and/or LINC02362. (D, E) EdU labeling to detect the percentage of dividing cells in LINC02362 and miR-516b-5p-overexpressing HCC cells (D) and the corresponding quantification (E; n=3). Bar=100μm. (F, G) Measurement (F) and quantification (G; n=3) of the cell cycle in HCC cells by flow cytometry. (H, I) Detection (H) and quantification (I; n=3) of apoptotic cells in HCC cells overexpressing LINC02362 and miR-516b-5p. * or # 0.01 < P < 0.05, ** or ## 0.001 < P < 0.01, *** or ### 0.0001 < P < 0.001, **** or #### P < 0.0001.